徐凤娟等

    [摘要] 目的 探讨米非司酮在子宫肌瘤合并中重度贫血患者术前预处理中的价值。 方法 选择2010年1月～2013年12月苏州大学附属太仓医院子宫肌瘤合并中重度贫血患者93例为研究对象，将其分为用药组(61例)和输血组(32例)。给予用药组患者口服米非司酮12.5 mg，每日1次，同时辅助以口服琥珀酸亚铁，待贫血纠正后住院手术治疗；输血组患者未用药，直接输血后手术治疗。比较分析两组患者的手术时间、术中出血量、住院费用、住院天数、术后发热及切口渗液等情况。 结果 治疗后，用药组患者的血红蛋白由(78.46±10.09)g/L上升到(104.23±19.71)g/L，差异有统计学意义(P 0.05)。 结论 术前短期应用小剂量米非司酮及口服补血药可以有效纠正子宫肌瘤合并中重度贫血者的贫血状态，降低医疗费用及手术对患者的损伤，同时节省血源以缓解用血紧张矛盾。

    [关键词] 子宫肌瘤；贫血；术前用药

    [中图分类号] R711.74 [文献标识码] A [文章编号] 1673-7210(2014)09(a)-0054-04

    [Abstract] Objective To investigate the preoperative value of Mifepristone in treatment of uterine leiomyoma with severe anemia. Methods 93 patients with uterine fibroids and moderate to severe anemia from January 2010 to December 2013 in Taicang Hospital of Suzhou University were selected as study objects， and they were divided into treatment group (61 cases) and blood transfusion group (32 cases). Patients of the treatment group were accepted mifepristone 12.5 mg orally， 1 time per day， and aided by oral amber acid ferrous at the same time， they were given the operation after anemia correction； patients in blood transfusion group were treated without medication ......